Bionor Pharma ASA: BIONOR PHARMA ASA - APPROVED PROSPECTUS AND DETAILS REGARDING SUBSEQUENT OFFERING

    Bionor Pharma ASA: BIONOR PHARMA ASA - APPROVED PROSPECTUS AND DETAILS
                        REGARDING SUBSEQUENT OFFERING

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES

(Oslo, 8 October 2013) Reference is made to the stock exchange announcements
made by Bionor Pharma ASA (the "Company") dated 12 September 2013 and 13
September 2013 regarding (i) a private placement (the "Private Placement") of
19,800,000 new shares in the Company (the "New Shares"), and (ii) the
subsequent offering (the "Subsequent Offering") of up to 7,500,000 additional
shares in the Company (the "Offer Shares").

The Financial Supervisory Authority of Norway has approved a prospectus (the
"Prospectus") for offering and listing of the Offer Shares on Oslo Børs.

The subscription period for the Subsequent Offering commences 8 October 2013
and expires at 16:30 hours (CET) on 22 October 2013. The subscription price
per
Offer Share is NOK 2.75, equal to the subscription price in the Private
Placement.

The Subsequent Offering will be directed towards existing shareholders as of
12 September 2013, as registered in the VPS on 17 September 2013 (the "Record
Date"), who were not allocated shares in the Private Placement and who are not
resident in a jurisdiction where such offering would be unlawful, or for
jurisdictions other than Norway, would require any filing, registration or
similar action, (the "Eligible Shareholders"). Eligible Shareholders have been
granted 1 non-transferable Allocation Rights for each 15.628227 existing
shares registered as of the Record Date rounded down to the nearest whole
subscription right. The Allocation Rights, subject to applicable laws, provide
rights to subscribe for and be allocated Offer Shares in the Offering.
Over-subscription and subscription without Allocation Rights will be
permitted. Allocation rights not used to subscribe for Offer Shares before the
end of the subscription period will lapse without compensation to the holder,
and consequently be of no value.

The Prospectus and subscription form for the Subsequent Offering is available
at www.bionorpharma.com or www.seb.no and in hard copy by contacting the
subscription office mentioned below or Bionor Pharma directly.

An information letter that includes information about where the Prospectus and
the subscription form will be available, the number of Allocation rights
allocated to the Eligible Shareholder and certain other matters relating to
the shareholding will be distributed to all Eligible Shareholders on or about
23 October 2013.

The subscription rights can be exercised by duly completing and delivering the
subscription form, in accordance with the terms and conditions set out in the
Prospectus, to the following subscription office:

Skandinaviska Enskilda banken AB (publ) Oslo branch
Filipstad Brygge 1
P.O. Box 1843 Vika
0123 Oslo
Norway
Tel: +47 22 82 70 00
Fax: +47 21 00 89 05

Norwegian residents with a Norwegian personal identification number can
subscribe online by accessing one of the web pages above.

Any questions or requests for assistance concerning the Subsequent Offering
should be directed to the subscription office mentioned above.

SEB is acting as sole manager for the Private Placement and the Subsequent
Offering.

For further information about the Subsequent Offering, reference is made to
the Prospectus.

For further information, please contact:
Synne H Røine, CFO Bionor, +47 99 22 98 92

About Bionor:
Bionor Pharma is a leading biotechnology company, searching for breakthrough
products for the treatment and prevention of life-threatening viral diseases.
The Company is listed on the Oslo Stock Exchange, and is developing vaccines
for viral infections. The vaccines are based on a proprietary technology
platform developed following more than two decades of research into peptides,
and they are designed to safely stimulate the immune system to combat viral
diseases.

More information about Bionor Pharma is available at www.bionorpharma.com

This publication is not for distribution, directly or indirectly, in or into
the United States, nor is it an offer for sale of or the solicitation of an
offer to purchase securities in the United States. Any securities referred to
herein have not been registered under the U.S. Securities Act of 1933, as
amended (the "U.S. Securities Act"), and may not be offered or sold in the
United States absent registration or pursuant to an exemption from
registration under the U.S. Securities Act. Copies of this publication are not
being, and may not be, distributed or sent into the United States.

This information is subject of the disclosure requirements acc. to §5-12
(Norwegian Securities Trading Act).



------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Bionor Pharma ASA via Thomson Reuters ONE
HUG#1734096
 
Press spacebar to pause and continue. Press esc to stop.